Common allergy-blocking antibodies in peanut allergy
Official title: Convergent allergen-specific antibodies in food allergy
Funded at Massachusetts General Hospital · NIH-11247507 · Data updated 2026-11-12
This project looks at antibodies from people with peanut allergy and after immunotherapy to learn how they stop allergic reactions and could help others with food allergies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 7, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $834,998 |
| NIH project number | 5R01AI182001-03 |
| Project ID | NIH-11247507 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with peanut allergy, especially those who have had or are considering oral immunotherapy, and who can provide blood or clinical history.
✕Less likely to help
People without IgE‑mediated food allergies or whose reactions are due to non‑allergic food intolerances are unlikely to benefit directly.
What this research studies
You might be asked to give blood or samples so researchers can isolate the antibodies your immune system makes against peanut proteins. The team will compare antibody sequences from many people to find shared, high‑affinity antibodies that target the same parts of the allergen. They will use lab tests and structural biology to see exactly where those antibodies bind and whether they block the IgE reactions that cause anaphylaxis. Findings could guide new antibody-based treatments or improve immunotherapy approaches.
Why it matters
Potential benefit: If successful, this work could lead to antibody therapies or improved immunotherapy that reduce severe allergic reactions to peanuts and other foods.
How similar studies have gone: Previous work, including by these investigators, has found neutralizing antibodies after oral immunotherapy, but turning those findings into widely used therapies is still early-stage.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Patil, Sarita U — Massachusetts General Hospital
- Study coordinator: Patil, Sarita U
Related research
Other NIH-funded projects on the same topics.
-
New Horizons in preventing and treating food allergy
A Johns Hopkins-led effort aims to advance how we prevent and treat food allergies across all ages by coordinating high-quality studies and developing better therapies.
-
New Horizons in Food Allergy Prevention and Treatment
A large, multi-site program at Johns Hopkins aims to advance prevention and treatment of food allergies across all ages.
-
Food allergy outcomes by race/ethnicity from infancy through adolescence
This study follows children with food allergies over time to understand how race and ethnicity relate to allergy management, outcomes, and quality of life.
-
Gut-brain links in food allergy responses
A research grant is exploring how signals between the gut and brain drive dangerous reactions to foods, with the goal of helping people with food allergies.
-
Targeting gut microbes to restore food-tolerance in adults
Aims to understand how gut bacteria and the lining of the gut interact to keep people with food allergies tolerant to what they eat.
-
Environment and early-life exposures shaping food allergy in children
This grant looks at how a child’s first year and their home environment may influence whether they develop food allergies, focusing on indoor exposures and microbes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.